Repligen Corp. Coverage Initiated by Analysts at Jefferies Group (RGEN)
Stock analysts at Jefferies Group initiated coverage on shares of Repligen Corp. (NASDAQ:RGEN) in a report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $17.00 price target on the stock. Jefferies Group’s target price suggests a potential upside of 24.36% from the company’s current price.
Shares of Repligen Corp. (NASDAQ:RGEN) opened at 13.96 on Tuesday. Repligen Corp. has a 52 week low of $7.37 and a 52 week high of $17.26. The stock has a 50-day moving average of $14.43 and a 200-day moving average of $13.12. The company has a market cap of $445.8 million and a P/E ratio of 27.34.
Repligen Corp. (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, March 6th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by $0.04. The company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $15.88 million. The company’s revenue for the quarter was down 18.1% on a year-over-year basis. Analysts expect that Repligen Corp. will post $0.24 EPS for the current fiscal year.
Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.